Global Osteoporosis Drugs Market 2015-2019 with Amgen, Eli Lilly, Merck & Novartis Dominating

May 20, 2015, 10:23 ET from Research and Markets

DUBLIN, May 19, 2015 /PRNewswire/ --Research and Markets

( has announced the addition of the "Global Osteoporosis Drugs Market 2015-2019" report to their offering.

The analysts forecast the global osteoporosis drugs market to grow at a CAGR of 4.14 percent over the period 2014-2019.

This report covers the present scenario and the growth prospects of the global osteoporosis drugs market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various osteoporosis drugs, including products with approved labeling and generic versions.

Promoting bone health awareness is important to help reduce the rate and risk of osteoporosis. Increased awareness among patients and physicians will lead to early disease diagnosis and treatment. This will also lead to better acceptability of osteoporosis drugs, thus increasing the drug penetration. The rise in the general awareness about osteoporosis has led to an increase in research funding and support for clinical and support services. Continued advances in risk assessment, screening, prevention, and treatment offer unique opportunities to improve bone health.

According to the report, the rise in life expectancy worldwide has led to an increase in the aging population. With aging, the incidence of osteoporosis and resulting osteoporotic fractures increases. The osteoporotic fractures among the elderly in the US are the highest in the world. In addition, though osteoporosis is more common in women than in men, the incidence in men is continuously increasing. Thus, the costs related to osteoporotic fractures have grown significantly, driving the market growth.

Further, the report states that the increasing number of patent expiries remains a major challenge that hinders the growth of the market.

Key vendors

  • Amgen
  • Eli Lilly
  • Merck
  • Novartis

Other prominent vendors

  • Abiogen Pharma
  • Deltanoid Pharmaceuticals
  • F. Hoffmann La Roche
  • GlaxoSmithKline
  • IMMD
  • Ligand Pharmaceuticals
  • NPS Pharma
  • Pantarhei Bioscience
  • Pfizer
  • PhytoHealth
  • Radius Health
  • Zosano Pharma

For more information visit

Media Contact: Laura Wood , +353-1-481-1716,

SOURCE Research and Markets